Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
about
Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagyAntiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein responseChemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA virusesKinase-Independent Small-Molecule Inhibition of JAK-STAT SignalingWP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells.ETS-targeted therapy: can it substitute for MEK inhibitors?Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.Deubiquitinating enzymes as promising drug targets for infectious diseases.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maLyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Targeting ubiquitination for cancer therapies.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Chronic myeloid leukemia stem cells and developing therapies.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Ubiquitin-specific proteases as cancer drug targets.Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges.Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.Proteasome-associated deubiquitinases and cancer.
P2860
Q27311286-D2772BA7-F0A8-4C2E-9973-8294EE902A71Q28481001-339678B9-B2F6-4BF3-A113-449CAC5E7E4EQ28537731-033BFBAE-7785-417F-93E5-93AF6EB75333Q28828592-BD5E8335-3136-4CCF-9C91-4B86D975764EQ33623142-88198B8B-6383-4B28-94FD-0BB69C629540Q33638827-42ECF431-2463-4BE3-AD18-2179C53DE43EQ33832937-381612BF-EB2F-44EC-9D43-B58025F47298Q33836097-94169A27-1407-4665-8B24-68C0F0C1D6ADQ34082540-C0748470-E743-4BA5-AB86-414D32326407Q34484344-C53814CB-42C4-4CBD-BBFA-EF25B5725CFFQ35559055-7F2EC23C-F9BD-4F9D-85E9-E00C8A1BA4C4Q35605318-E866906B-9579-43DE-904D-D978CEAE4C55Q36508969-8973B57C-E038-4575-A34F-ACF0461D7A8CQ37158445-A185C2ED-D11D-4875-933C-18B40B991BB3Q37256808-C122A760-CB7B-4677-9B8B-C812591F4749Q37369672-285A2190-C03D-4230-84C3-254C75893FC5Q37660030-4739A881-0B68-4735-9FAB-E8F90F108369Q37663655-3C75AA6A-689A-4443-8F04-68445A956602Q37836936-B355C142-70FF-4DE5-8D5B-3D439B65B41BQ37847179-5F81A6B0-98C0-4EFF-A887-E312EC4047E3Q37875076-94CE2F7D-AEEF-4417-864D-10D38AC4D47AQ37911537-A87D3E87-513B-45B6-BE47-69A8BE979293Q38695071-7B3733E1-D921-44FE-9DD3-5CF993B16723Q38943401-230A8182-F204-4964-910F-295E7857978EQ38989377-ABDAFDF0-2D6C-4079-82CC-55A0AF254687Q39161582-247A259E-839D-4DE9-9517-7D67A566E89FQ42316726-42224C49-0549-4396-968F-32941CA83DF8Q42908737-CFA6AE31-7474-4B79-848A-8EAB0B8BFDD4Q43131498-745F30C1-2B86-4D93-9020-720DE33B2ED9Q47161331-0AFCAC6E-6033-4074-AB9C-369F787B3E3D
P2860
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@ast
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@en
type
label
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@ast
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@en
prefLabel
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@ast
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@en
P2093
P2860
P1433
P1476
Activation of a novel Bcr/Abl ...... nic myelogenous leukemia cells
@en
P2093
Geoffrey A Bartholomeusz
Ling Yuan Kong
Moshe Talpaz
Nicholas J Donato
Shimei Wang
Vaibhav Kapuria
Waldemar Priebe
P2860
P304
P356
10.1182/BLOOD-2006-02-005579
P407
P50
P577
2007-01-03T00:00:00Z